New case of trichorinophalangeal syndrome-like phenotype with a de novo t(2;8)(p16.1;q23.3) translocation which does not disrupt the TRPS1 gene
© Crippa et al.; licensee BioMed Central Ltd. 2014
Received: 24 August 2013
Accepted: 24 April 2014
Published: 2 May 2014
Trichorhinophalangeal syndrome (TRPS) is a rare autosomal dominant genetic disorder characterised by distinctive craniofacial and skeletal abnormalities. TRPS is generally associated with mutations in the TRPS1 gene at 8q23.3 or microdeletions of the 8q23.3-q24.11 region. However, three deletions affecting the same chromosome region and a familial translocation t(8;13) co-segregating with TRPS, which do not encompass or disrupt the TRPS1 gene, have been reported. A deregulated expression of TRPS1 has been hypothesised as cause of the TRPS phenotype of these patients.
We report the clinical and molecular characterisation of a 57-year-old Caucasian woman carrying the t(2;8)(p16.1;q23.3) de novo balanced translocation. The proband presented with peculiar clinical features (severe craniofacial dysmorphism, alopecia universalis, severe scoliosis, mitral valve prolapse, mild mental impairment and normal growth parameters) that partially overlap with TRPS I. Mutational and array CGH analyses ruled out any genetic defect affecting TRPS1 or genomic alteration at the translocation breakpoint or elsewhere in the genome. Breakpoint mapping excluded disruption of TRPS1, and revealed that the chromosome 8q23.3 breakpoint was located within the IVS10 of the long intergenic non-coding RNA LINC00536, at approximately 300 kb from the TRPS1 5’ end. Conversely, the 2p16.1 breakpoint mapped within a LINE sequence, in a region that lacks transcriptional regulatory elements. As a result of the translocation, nucleotide base pair additions and deletions were detected at both breakpoint junction fragments, and an evolutionarily conserved VISTA enhancer element from 2p16.1 was relocated at approximately 325 kb from the TRPS1 promoter.
We suggest that the disruption of the genomic architecture of cis regulatory elements downstream the TRPS1 5′ region, combined with the translocation of a novel enhancer element nearby TRPS1, might be the pathogenetic mechanism underpinning the proband’s phenotype. The clinical and genetic characterisation of the present subject allowed us to make a genetic diagnosis in the context of a known syndrome, contributing to a better comprehension of the complex transcriptional regulation of TRPS1 and TRPS ethiopathogenesis.
KeywordsReciprocal translocation Conserved enhancer element TRPS TRPS1
Trichorhinophalangeal syndrome (TRPS) is a complex malformative disorder with autosomal dominant inheritance that is characterised by distinctive craniofacial and skeletal abnormalities . TRPS patients generally present slow-growing and sparse scalp hair, medially thick and laterally thin eyebrows, a bulbous pear-shaped nose, a long flat philtrum, a thin upper vermilion border, large protruding ears , and bone abnormalities including mild to severe brachydactyly, cone-shaped epiphyses, hip dysplasia and short stature . Malformations of inner organs have also been reported .
Three TRPS types can be distinguished at the clinical and molecular levels: TRPS I, II and III . TRPS I (OMIM 190350) occurs as a consequence of inactivating mutations or chromosomal abnormalities that delete or disrupt the TRPS1 gene [1, 4–7]. TRPS II (OMIM 150230) is a contiguous gene syndrome caused by heterozygous deletions in 8q23.3–q24.11 involving the TRPS1 and EXT1 genes [8, 9]. TRPS II is phenotypically distinguished from TRPS I by the presence of multiple cartilaginous exostoses and other less frequent features, such as intellectual disability, lax skin and a tendency toward bone fractures. Finally, TRPS III (OMIM 190351) is the result of missense mutations in the region of TRPS1 that encodes a GATA-type zinc finger domain [2, 6, 10]. The primary clinical difference between TRPS I and TRPS III is in the severity of the skeletal abnormalities, especially brachydactyly and short stature .
The high dosage sensitivity of the TRPS1 gene is underscored by mosaicism in some reported cases . Moreover, a perturbation of TRPS1 expression was previously hypothesised as causative in three TRPS II patients. These patients carried deletions at chromosome 8q24, which encompassed only the EXT1 gene. In two of them, the proximal breakpoint was established and occurred at approximately 99.3 and 600–800 kb, respectively, from the TRPS1 5′ end [12–14]. Furthermore, a familial translocation t(8;13)(q23.3;q21.31), which did not disrupt TRPS1 and co-segregated with TRPS I, was recently described . In this case, the translocation resulted in the disruption of a transposon type I element, located at 87 kb from the TRPS1 5′ end, and in the simultaneous relocation of a non-coding conserved VISTA enhancer element from 13q21.31 within the TRPS1 5′ region, apparently leading to an increase in TRPS1 gene expression in the translocation carriers .
In the current study, we report on a proband with a t(2;8)(p16.1;q23.3) de novo reciprocal chromosomal translocation who exhibits peculiar clinical features which mainly overlap with TRPS I. This is the second case in which a translocation breakpoint (bkp) does not interrupt the TRPS1 gene and is not associated with its deletion. As in the previous report, identification of the bkps at nucleotide resolution suggests that, first the disruption and possibly the removal of TRPS1 cis regulatory elements and then the relocation of a conserved VISTA enhancer element nearby the TRPS1 5′ end, may be the cause of the proband’s unusual phenotype.
The proband is a 57-year-old Caucasian woman, born after an uncomplicated pregnancy to non-consanguineous healthy parents. The auxological parameters at birth were on the 50th percentile.
During childhood and adolescence growth was normal until a final height of 165 cm was reached, consistent with the proband’s midparental target height (167 cm). Psychomotor development was normal. Menarche occurred at 14 years, and menses have always been regular until menopause, which occurred at 45 years after surgery for hysterectomy. The proband showed no hair growth from early childhood and this rapidly progressed to alopecia universalis (i.e., absence of eyebrows and, after puberty, absence of pubic and axillary hair).
After the age of 15 years, the proband experienced several episodes of falls without loss of consciousness, but all neurological examinations performed (MRI, EMG and EEG) appeared normal. Echocardiogram revealed prolapse of both mitral valve leaflets and slight mitral regurgitation. After regular cardiologic follow-up, valve replacement was performed at the age of 45 years. Intraoperative findings revealed thickened mitral valve leaflets with the appearance of myxomatous degeneration, as confirmed by histological analysis. In the same year, the proband had a hysterectomy due to the presence of several fibroids, but the ovaries were preserved. Before surgery, she also suffered from a severe uterine prolapse.
We saw the proband for the first time at the age of 51, as she was referred to an endocrinology outpatient clinic because of hyperparathyroidism related to vitamin D deficiency. Endocrinology and genetic analyses were performed, with the aim of confirming a diagnosis of familial hyperparathyroidism based on the primary hyperparathyroidism of her mother. No germ-line mutations of the multiple endocrine neoplasia I (MEN1) gene were observed. Consequently, a diagnosis of tertiary hyperparathyroidism resulting from autonomous activity of the parathyroid glands, related to long-standing vitamin D deficiency, was raised. In addition, high levels of glycosylated haemoglobin (8%; reference range 4.5–6.5%) were observed, and the proband underwent metformin therapy. Bone mineral density evaluated by dual energy X-ray absorptiometry (Hologic) revealed vertebral and femoral osteoporosis (lumbar spine T score of −3.5 and femoral neck T score of −2.5), which was considered secondary to the endocrinological problems. There was no history of urolithiasis or nephrocalcinosis. Abdominal ultrasound analysis was normal, and only a nephroptosis of the right kidney was apparent. In addition, the proband’s mother referred a very high pain threshold in her daughter, who, for example, never required analgesia after surgery. The proband exhibited an important visual impairment characterised by severe astigmatism, cataracts and photophobia.
Physical examination revealed several craniofacial anomalies suggestive of a genetic disease: universal alopecia, deep-set eyes, bulbous pear-shaped nose, elongated philtrum, thin upper lip, high-arched palate, and large and prominent ears. The proband referred that her craniofacial dysmorphisms had been partially corrected by plastic surgery at the age of 43 years, particularly in the periorbital, maxillary, and mandibular areas, suggesting the presence of severe facial bone anomalies. However, we cannot confirm these information as she would not grant permission for us to see pre-surgery facial photographs and the surgery report was not available. Finally, she showed bilateral valgi and flat feet, and an anxious and obsessive psychological attitude. Cognitive function was not formally evaluated.
The observed clinical findings suggested a diagnosis of Trichorhinophalangeal syndrome. Therefore, a radiological study of the skeleton was performed; this revealed hypoplastic mandibular condyles and severe scoliosis. No abnormalities were observed in hands (Additional file 1: Figure S1), arms, legs and pelvis. At age 56 an infiltrating ductal carcinoma, sized 11 cm, was identified in the right breast, and was subsequently removed by mastectomy. Histological examination characterised the cancer as oestrogen-negative, and the proband is currently undergoing chemotherapy.
The proband does not accept the genetic basis for her condition, and denied permission to release her photos for publication.
Conventional cytogenetic analysis was performed on the proband and her healthy parents on QFQ-banded metaphases prepared from peripheral blood lymphocytes using standard procedures. The karyotypes were described in accordance with ISCN (2009) .
High-resolution array comparative genomic hybridisation (CGH) analysis
Genomic DNA was extracted from whole blood using the GenElute Blood Genomic DNA kit (Sigma-Aldrich, St. Louis, MO). Array CGH analysis was performed using the Human Genome CGH Microarray Kit 244 K (Agilent Technologies, Palo Alto, CA). From both test and normal reference samples, 3 μg of DNA were processed according to the manufacturer’s instructions. Images were captured using the Agilent Feature Extraction 9.1 software and chromosomal profile was acquired using the ADM-2 algorithm provided by DNA Analytics software (v4.0) (Agilent Technologies).
Fluorescence in situ hybridisation (FISH) analysis
FISH mapping of the bkps was performed using BAC clones, targeting the chromosomal bkp regions 2p16.1-p15 and 8q23.3-q24.1, as probes. The clones were provided by Invitrogen ltd (Carlsbad, CA, USA), and selected by consulting the UCSC Genome Browser Database (University of California Santa Cruz, reference genome assembly GRCh37/hg19) . All BAC clone DNAs were labelled by nick-translation with Cy3-dUTP (GE Healthcare, Little Chalfont, Buckinghamshire, UK) and the FISH protocol described by Lichter and Cremer  was followed, with minor modifications.
The 2p breakpoint was further narrowed down by means of three contiguous overlapping 15-kb long-range polymerase chain reaction (LR-PCR) products as probes (LRP I, II, III). The fragments were amplified by LR-PCR using the TaKaRa LA Taq™ kit (Takara Bio Inc., Shiga, Japan) using approximately 100 ng of BAC clone CTD-2562H20 as template, and then labelled by random priming (Prime-It Fluor Fluorescence labelling kit, Stratagene, Amsterdam, Netherlands). The primer pairs are shown in Additional file 2: Table S1.
Amplification of the junction fragments
Primers used for amplification of der(2) and der(8) junction fragments
Primer sequence (5′→3′)
Primer localization a
PCR size (bp)
Der(8) junction fragment
Der(2) junction fragment
The entire coding sequence, intron-exon junctions and untranslated exons of the TRPS1 gene (RefSeq Accession: NM_014112.4) were amplified for mutation screening by PCR using the AmpliTaq Gold® kit (Applied Biosystems). The primer pairs and amplification conditions are summarized in Additional file 4: Table S3. Sequencing was performed as described before.
Standard cytogenetic analysis revealed in the proband a de novo apparently balanced reciprocal chromosome translocation between the short arm of chromosome 2 and the long arm of chromosome 8 [t(2;8)(p15;q24.1)]. The proband’s parents had normal karyotypes. The subsequent high-resolution array CGH analysis excluded the presence in the proband of rare CNVs spanning the translocation bkp chromosomal bands or localized elsewhere in the genome.
Additional mutations within TRPS1 were excluded in the proband by sequence analysis.
We have herein described a proband with an unusual presentation of TRPS I, who was found to carry a de novo reciprocal translocation involving the 2p16.1 and 8q23.3 chromosomal bands. The proband represents an atypical case as she does not bear a microdeletion involving TRPS1 or a mutation in the gene coding sequence, and characterisation of her translocation bkps excluded the disruption of the TRPS1 gene. The sequence analysis of the bkp junction fragments, however, precisely located the 8q23.3 bkp on chromosome der(8) at approximately 300 kb from the TRPS1 5′ end, thus pointing to TRPS1 as the gene responsible for the proband’s TRPS I phenotype. In addition, nucleotide base pair additions and deletions were detected, thus indicating that the translocation was likely mediated by the Non-Homologous End Joining (NHEJ) mechanism .
As previously reported in a t(8;13)(q23.3;q21.31) familial translocation co-segregating with TRPS I , in the present subject neither bkp occurs within a coding region. However, the rearrangement interrupts and changes the positions of gene regulatory elements with respect to their original gene targets. We suggest that the disruption and the possible removal of TRPS1 cis regulatory elements, such as the LINC00536, might be causative, consistent with the previous hypotheses in a few reported patients [12–15]. To date, neither the precise biological function nor the target gene/s of LINC00536 are known. However, as lincRNAs are key regulators of diverse cellular processes , we hypothesize that LINC00536 disruption might have contributed to the onset of the proband’s clinical phenotype. Interestingly, the 8q23.3 bkp likely interrupts a putative enhancer region [23, 24] (Additional file 5: Figure S2B), and maps within a genomic region where DNA sequences interacting with transcription factors, identified by ChIP-seq experiments, have been localized [25, 26] (Additional file 5: Figure S2B).
Notably, the 2p16.1 bkp was positioned at approximately 25 kb proximal to the conserved VISTA enhancer element hs836, whose activity in facial mesenchyme development has been substantiated by gene reporter assays in mouse embryos . Similarly to what recently reported by David et al. , in the present subject the enhancer element was relocated by the translocation in the vicinity of the TRPS1 5′ end, thus suggesting a possible “enhancer adoption”, a mechanism recently described by Lettice et al. , which might have perturbed TRPS1 expression in the facial region during embryonic development. In agreement with this hypothesis, David et al.  detected an apparently TRPS1 overexpression in the translocation carriers compared with controls.
There are many potential consequences resulting from chromosomal rearrangements that could lead to position effects and thus cause human disease. These include the moving away of an enhancer or a locus control region from its gene, the juxtaposition of a gene with a regulatory element from another gene, and the removal of a boundary element or a long-range insulator [28, 29]. On this basis, the unique reshaping of regulatory elements occurring in the proband could have deregulated the expression of TRPS1, thus leading to the observed clinical phenotype. However, we could not demonstrate any alteration in TRPS1 expression as preliminary TRPS1 gene expression assays, performed from the proband’s peripheral blood, gave inconclusive results due to very different TRPS1 expression levels found in controls (Additional file 6: Figure S3).
The peculiar chromosome rearrangement herein described could also explain the differences of both the craniofacial and skeletal abnormalities of our proband from those normally found in TRPS patients. Indeed, important skeletal features of TRPS I such as short stature, brachydactyly, and the pathognomonic abnormality of cone-shaped epiphyses were not observed (Additional file 1: Figure S1). In addition, the proband exhibited the main TRPS facial dysmorphism as well as bone anomalies from early infancy; but these were so severe as to require plastic surgery. Such severe abnormalities, possibly accounted for by significant TRPS1 deregulation in the facial mesenchyme during development, are not frequently associated with TRPS. The proband also displayed an important scoliosis and alopecia universalis, clinical findings that are markedly more severe than those normally observed in TRPS patients.
Genotype-phenotype correlations were hard to assess for a few clinical signs, namely minor mental impairment, diabetes and a mild clinical presentation of connective tissue disorder (mild joint laxity, severe astigmatism, renal ptosis, and uterine prolapses). These symptoms may be caused by mutations of unknown genes, although a contribution of the chromosomal rearrangement in deregulating breakpoint-neighbouring genes cannot be ruled out. Similarly, we cannot exclude the possible influence of the translocation, via altered gene expression, on the development of breast cancer. Indeed, TRPS1 gene overexpression in more than 90% of breast cancers has been reported .
To conclude, this case report, presenting a new case of association of TRPS I-like phenotype with a reciprocal chromosomal translocation which does not disrupt the TRPS1 coding sequence, increases the number of TRPS patients whose pathologic phenotype is caused by a functional disturbance of TRPS1. The clinical and genetic characterisation of the present subject allowed us to make a genetic diagnosis in the context of a known syndrome, contributing to expand the TRPS phenotypic spectrum. In addition, this study provides a further comprehension of the complex transcriptional regulation of developmental genes such as TRPS1. The identification and mapping at nucleotide level of novel genomic alterations in TRPS patients will be necessary to better understand the pathogenesis of Trichorhinophalangeal syndrome and the regulation of TRPS1.
Written informed consent was obtained from the proband for publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
- Array CGH:
Array comparative genomic hybridisation
Bacterial artificial chromosome
Fluorescence in Situ hybridisation
Long-range PCR probe
Magnetic resonance imaging
Non-homologous end joining
Polymerase chain reaction
Reverse transcription quantitative PCR
University of California Santa Cruz.
The authors would like to thank the proband’s family for their collaboration. We also thank Dr. Fiorenza Bellini and Dr. Maria Teresa Bonati for their help in the clinical review. This study was supported by a Ministry of Health grant “Ricerca Corrente” to Istituto Auxologico Italiano IRCCS (08C604-2005).
- Momeni P, Glöckner G, Schmidt O, von Holtum D, Albrecht B, Gillessen-Kaesbach G, Hennekam R, Meinecke P, Zabel B, Rosenthal A, Horsthemke B, Lüdecke HJ: Mutations in a new gene, encoding a zinc-finger protein, cause tricho-rhino-phalangeal syndrome type I. Nat Genet. 2000, 24: 71-74.View ArticlePubMedGoogle Scholar
- Hilton MJ, Sawyer JM, Gutiérrez L, Hogart A, Kung TC, Wells DE: Analysis of novel and recurrent mutations responsible for the tricho-rhino-phalangeal syndromes. J Hum Genet. 2002, 47: 103-106.View ArticlePubMedGoogle Scholar
- Rué M, Lüdecke HJ, Sibon I, Richez C, Taine L, Foubert-Samier A, Arveiler B, Schaeverbeke T, Lacombe D, Tison F, Goizet C: Rheumatologic and neurological events in an elderly patient with tricho-rhino-phalangeal syndrome type I. Eur J Med Genet. 2011, 54: e405-e408.View ArticlePubMedGoogle Scholar
- Hamers A, Jongbloet P, Peeters G, Fryns JP, Geraedts J: Severe mental retardation in a patient with tricho-rhino-phalangeal syndrome type I and 8q deletion. Eur J Pediatr. 1990, 149: 618-620.View ArticlePubMedGoogle Scholar
- Marchau FE, Van Roy BC, Parizel PM, Lambert JR, De Canck I, Leroy JG, Gevaert CM, Willems PJ, Dumon JE: Tricho-rhino-phalangeal syndrome type I (TRP I) due to an apparently balanced translocation involving 8q24. Am J Med Genet. 1993, 45: 450-455.View ArticlePubMedGoogle Scholar
- Lüdecke HJ, Schaper J, Meinecke P, Momeni P, Gross S, von Holtum D, Hirche H, Abramowicz MJ, Albrecht B, Apacik C, Christen HJ, Claussen U, Devriendt K, Fastnacht E, Forderer A, Friedrich U, Goodship TH, Greiwe M, Hamm H, Hennekam RC, Hinkel GK, Hoeltzenbein M, Kayserili H, Majewski F, Mathieu M, McLeod R, Midro AT, Moog U, Nagai T, Niikawa N, Orstavik KH, et al: Genotypic and phenotypic spectrum in tricho-rhino-phalangeal syndrome types I and III. Am J Hum Genet. 2001, 68: 81-91.View ArticlePubMedGoogle Scholar
- Kaiser FJ, Brega P, Raff ML, Byers PH, Gallati S, Kay TT, de Almeida S, Horsthemke B, Lüdecke HJ: Novel missense mutations in the TRPS1 transcription factor define the nuclear localization signal. Eur J Hum Genet. 2004, 12: 121-126.View ArticlePubMedGoogle Scholar
- Lüdecke HJ, Wagner MJ, Nardmann J, La Pillo B, Parrish JE, Willems PJ, Haan EA, Frydman M, Hamers GJ, Wells DE, Horsthemke B: Molecular dissection of a contiguous gene syndrome: localization of the genes involved in the Langer-Giedion syndrome. Hum Mol Genet. 1995, 4: 31-36.View ArticlePubMedGoogle Scholar
- Shanske AL, Patel A, Saukam S, Levy B, Lüdecke HJ: Clinical and molecular characterization of a patient with Langer-Giedion syndrome and mosaic del(8)(q22.3q24.13). Am J Med Genet A. 2008, 146A: 3211-3216.View ArticlePubMedGoogle Scholar
- Piccione M, Niceta M, Antona V, Di Fiore A, Cariola F, Gentile M, Corsello G: Identification of two new mutations in TRPS 1 gene leading to the tricho-rhino-phalangeal syndrome type I and III. Am J Med Genet A. 2009, 149A: 1837-1841.View ArticlePubMedGoogle Scholar
- Niikawa N, Kamei T: The Sugio-Kajii syndrome, proposed tricho-rhino-phalangeal syndrome type III. Am J Med Genet. 1986, 24: 759-760.View ArticlePubMedGoogle Scholar
- Wuyts W, Roland D, Lüdecke HJ, Wauters J, Foulon M, Van Hul W, Van Maldergem L: Multiple exostoses, mental retardation, hypertrichosis, and brain abnormalities in a boy with a de novo 8q24 submicroscopic interstitial deletion. Am J Med Genet. 2002, 113: 326-332.View ArticlePubMedGoogle Scholar
- McBrien J, Crolla JA, Huang S, Kelleher J, Gleeson J, Lynch SA: Further case of microdeletion of 8q24 with phenotype overlapping Langer-Giedion without TRPS1 deletion. Am J Med Genet A. 2008, 146A: 1587-1592.View ArticlePubMedGoogle Scholar
- Pereza N, Severinski S, Ostojić S, Volk M, Maver A, Dekanić KB, Kapović M, Peterlin B: Third case of 8q23.3-q24.13 deletion in a patient with Langer-Giedion syndrome phenotype without TRPS1 gene deletion. Am J Med Genet A. 2012, 158A: 659-663.View ArticlePubMedGoogle Scholar
- David D, Marques B, Ferreira C, Araújo C, Vieira L, Soares G, Dias C, Pinto M: Co-segregation of trichorhinophalangeal syndrome with a t(8;13)(q23.3;q21.31) familial translocation that appears to increase TRPS1 gene expression. Hum Genet. 2013, 132: 1287-1299.View ArticlePubMedGoogle Scholar
- Shaffer LG, Slovak ML, Campbell LJ: ISCN An International System for Human Cytogenetic Nomenclature. 2009, Basel: S. KargerGoogle Scholar
- The UCSC Human Genome Browser Database. [http://genome.ucsc.edu]
- Lichter P, Cremer T: Chromosome analysis by non-isotopic in situ hybridization. Human Cytogenetics A Practical Approach. Edited by: Rooney DE, Czipolkowski BH. 1992, Oxford: Oxford University Press, 157-192.Google Scholar
- The VISTA Enhancer Browser Database. [http://enhancer-test.lbl.gov]
- Pollard KS, Hubisz MJ, Rosenbloom KR, Siepel A: Detection of non neutral substitution rates on mammalian phylogenies. Genome Res. 2009, 20: 110-121.View ArticlePubMedGoogle Scholar
- Shaw CJ, Lupski JR: Non-recurrent 17p11.2 deletions are generated by homologous and non-homologous mechanisms. Hum Genet. 2005, 116: 1-7.View ArticlePubMedGoogle Scholar
- Guttman M, Donaghey J, Carey BW, Garber M, Grenier JK, Munson G, Young G, Lucas AB, Ach R, Bruhn L, Yang X, Amit I, Meissner A, Regev A, Rinn JL, Root DE: Lander ES: lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature. 2011, 477: 295-300.View ArticlePubMedPubMed CentralGoogle Scholar
- Ernst J, Kellis M: Discovery and characterization of chromatin states for systematic annotation of the human genome. Nat Biotechnol. 2010, 28: 817-825.View ArticlePubMedPubMed CentralGoogle Scholar
- Ernst J, Kheradpour P, Mikkelsen TS, Shoresh N, Ward LD, Epstein CB, Zhang X, Wang L, Issner R, Coyne M, Ku M, Durham T, Kellis M, Bernstein BE: Mapping and analysis of chromatin state dynamics in nine human cell types. Nature. 2011, 473: 43-49.View ArticlePubMedPubMed CentralGoogle Scholar
- Hudson ME, Snyder M: High-throughput methods of regulatory element discovery. Biotechniques. 2006, 41: 673-681.View ArticlePubMedGoogle Scholar
- Euskirchen GM, Rozowsky JS, Wei CL, Lee WH, Zhang ZD, Hartman S, Emanuelsson O, Stolc V, Weissman S, Gerstein MB, Ruan Y, Snyder M: Mapping of transcription factor binding regions in mammalian cells by ChIP: comparison of array- and sequencing-based technologies. Genome Res. 2007, 17: 898-909.View ArticlePubMedPubMed CentralGoogle Scholar
- Pennacchio LA, Ahituv N, Moses AM, Prabhakar S, Nobrega MA, Shoukry M, Minovitsky S, Dubchak I, Holt A, Lewis KD, Plajzer-Frick I, Akiyama J, De Val S, Afzal V, Black BL, Couronne O, Eisen MB, Visel A, Rubin EM: In vivo enhancer analysis of human conserved non-coding sequences. Nature. 2006, 444: 499-502.View ArticlePubMedGoogle Scholar
- Lettice LA, Daniels S, Sweeney E, Venkataraman S, Devenney PS, Gautier P, Morrison H, Fantes J, Hill RE, FitzPatrick DR: Enhancer-adoption as a mechanism of human developmental disease. Hum Mutat. 2011, 32: 1492-1499.View ArticlePubMedGoogle Scholar
- Kleinjan DA, van Heyningen V: Long-range control of gene expression: emerging mechanisms and disruption in disease. Am J Hum Genet. 2005, 76: 8-32.View ArticlePubMedGoogle Scholar
- Radvanyi L, Singh-Sandhu D, Gallichan S, Lovitt C, Pedyczak A, Mallo G, Gish K, Kwok K, Hanna W, Zubovits J, Armes J, Venter D, Hakimi J, Shortreed J, Donovan M, Parrington M, Dunn P, Oomen R, Tartaglia J, Berinstein NL: The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. Proc Natl Acad Sci U S A. 2005, 102: 11005-11010.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/15/52/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.